Skip to main content
SP5007,712.79-0.24%DOW53,561.74-0.01%NASDAQ26,412.69-0.48%BTC$77,657.00-2.98%ETH$2,437.61-2.89%GOLD$4,511.40-3.27%OIL$83.28-0.30%
Smart Investors Daily
Sign InSign Up Free
Exagen Inc. logo

NASDAQ · XGN

Exagen Inc.

Healthcare · Medical - Diagnostics & Research

$7.52

Down-$0.11 (-1.46%)

Updated Aug 28, 2026, 5:57 PM

SID Score

5.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
163.17M
P/E ratio
-8.94
Dividend yield
0.00%
52-week range
$2.59 – $7.99
Volume
161.7K
Avg. volume
318.13K

Price performance

XGN price history

1M range · 0 trading sessions · Daily adjusted prices

XGN does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest XGN news

The latest Smart Investors Daily articles mentioning XGN.

Stock researchCompany · Overview

XGN research

Overview

Company profile and research snapshot.

Company profile

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$13.33
Implied upside
—
Analysts
—
XGN recent ratings
DateFirmRatingTarget
Aug 5, 2026BTIGBuy—
Aug 5, 2026B. Riley SecuritiesBuy—
Aug 5, 2026TD CowenBuy—
Jun 25, 2026Roth CapitalBuy—
May 12, 2026BTIGBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 6, 2026

Exagen (XGN) Stock Gets Fair Value Boost As Analysts Weigh Growth And Execution

Exagen now carries a modestly higher implied fair value, with the target shifting from about US$8.67 to roughly US$9.71 per share. Analysts link this change to a mix of optimism around the AVISE CTD autoimmune testing portfolio and caution around execution and valuation, as they assess how the current business can support the updated target. Read on to see what this may mean for you as an investor and how to track the evolving Exagen narrative from here. Analyst Price Targets don't always...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By